Luspatercept, 25 mg, 75 mg Suppliers & Bulk Manufacturers
Available Forms: Lyophilized powder for subcutaneous injection
Available Strengths: 25 mg, 75 mg
Reference Brands: Reblozyl
Category: Anemia
Luspatercept (Reblozyl) is an FDA and EMA-approved biologic used to treat anemia in beta thalassemia and MDS patients. It reduces transfusion needs by enhancing red blood cell production. Offered in GMP-certified form, ideal for pharma B2B buyers, distributors, and exporters. Contact us for bulk supply and regulatory support.
Product Description:
Luspatercept is a groundbreaking erythroid maturation agent used to treat anemia in patients with beta thalassemia and myelodysplastic syndromes (MDS). Marketed under the brand name Reblozyl, it is approved by the FDA and EMA for reducing red blood cell transfusion dependence. Luspatercept is a recombinant fusion protein administered via subcutaneous injection and produced under strict GMP compliance. Ideal for pharmaceutical distributors, wholesalers, and B2B partners seeking high-demand biologics. We offer global bulk supply, regulatory support, and competitive pricing for Luspatercept. Partner with us for reliable sourcing and efficient delivery. Contact us now for Luspatercept export and distribution solutions.
Luspatercept, — third party manufacturing & bulk supply
Luspatercept, 25 mg, 75 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Luspatercept, listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Luspatercept, →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Luspatercept is used to treat anaemia in adults with beta-thalassemia who require regular red blood cell transfusions. It is also used in certain patients with myelodysplastic syndromes (MDS) to reduce the need for blood transfusions.
It is made from a recombinant fusion protein that binds to specific TGF-beta superfamily ligands, helping enhance late-stage red blood cell maturation in the bone marrow.
The trade name is Reblozyl.
Luspatercept (Reblozyl) is manufactured by Bristol Myers Squibb in collaboration with Acceleron Pharma.
The generic name is Luspatercept-aamt.
The brand name is Reblozyl.
It is manufactured in the United States and other approved Bristol Myers Squibb production sites globally.
Related Products
Mitapivat Sulfate
Strength:
5 mg, 20 mg, 50 mg
Form: Tablets
Reference Brands: Pyrukynd (USA)
View Details
Eltrombopag Cholin 50 Mg Tablet
Strength:
12.5 mg, 25 mg, 50 mg, and 75 mg
Form: Tablets / Oral suspension
Reference Brands: Promacta (USA), Revolade (EU)
View Details
Epoetin Alfa
Strength:
1,000 IU, 2,000 IU, 4,000 IU, 10,000 IU, 40,000 IU
Form: injection (prefilled syringe)
Reference Brands: EPOGEN (USA), PROCRIT (USA)
View DetailsQuick Response Guaranteed | Verified Suppliers
